METHOXSALEN

Post-LOE

methoxsalen

Teva

ANDAORALCAPSULE

Approved

Jun 2015

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

5/8 — Partial

METHOXSALEN (methoxsalen) by Teva is ii. Approved for psoriasis. First approved in 2015.

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

II. CLINICAL PHARMACOLOGY The combination treatment regimen of psoralen (P) and ultraviolet radiation of 320-400 nm wavelength commonly referred to as UVA is known by the acronym, PUVA. Skin reactivity to UVA (320–400 nm) radiation is markedly enhanced by the ingestion of methoxsalen. In a well…

Worked on METHOXSALEN at Teva? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

METHOXSALEN

Mechanism of Action

Indications (1)

Clinical Trials (1)